Pyrexia, commonly known as fever, is a clinical symptom frequently encountered in medical practice. It is a physiological response to a variety of conditions, most commonly infectious diseases. Understanding the pathophysiology, identifying the cause, and managing fever effectively are critical to patient care.
Pyrexia is the body's adaptive response to pathologic conditions, primarily infections. The hypothalamus, acting as the body's thermostat, raises the set-point temperature in response to pyrogens. These can be endogenous, such as cytokines, or exogenous like microbial toxins. This results in the characteristic symptoms of fever.
Identifying the cause of pyrexia is crucial for targeted treatment. A detailed history and physical examination often provide valuable clues. Laboratory tests, including complete blood count, cultures, and imaging studies, may be necessary in some cases. Infections are the most common cause, but non-infectious causes such as malignancies, autoimmune diseases, and drug reactions should also be considered.
Management of pyrexia involves treating the underlying cause and symptomatic relief. Antipyretics, such as paracetamol and non-steroidal anti-inflammatory drugs, are commonly used for symptomatic relief. However, their use should be balanced against potential side effects. In cases where the cause of fever is unclear, empirical antimicrobial therapy may be initiated while investigations are ongoing.
Management of pyrexia may differ in special populations, such as children, pregnant women, and immunocompromised patients. In these groups, the risk of serious infections is higher, and a more cautious approach is often warranted. Additionally, the choice of antipyretics may be limited due to safety concerns.
Pyrexia is a common clinical symptom with a wide range of causes. A systematic approach to identifying the cause and managing the fever effectively is essential. Further research is needed to refine our understanding of the pathophysiology of fever and to develop more effective antipyretic therapies.
1.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
2.
Sevabertinib Approved for First-Line Mutated NSCLC
3.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
4.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
5.
AI can identify women at risk of breast cancer years in advance: Study
1.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
2.
Pediatric Tumor Microenvironment Evolution: Mechanisms, Clinical Impact, and Therapeutic Implications
3.
Hematopoietic Stem Cell Activity Biomarkers in Aging
4.
Bone-Marrow Immune Cell Competition: Mechanisms, Clinical Implications, and Emerging Therapeutic Perspectives
5.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Emerging Concepts in Hematology
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation